Jonathan Webster, MD, and Nikesh Shah, MD, discuss ALL data and research to look out for at ASH 2025.

Ongoing Research to Watch at ASH 2025 and Beyond

Jonathan Webster, MD, and Nikesh Shah, MD, highlight key ALL data anticipated at the 2025 ASH Annual Meeting, including updates from pivotal immunotherapy studies and trials exploring targeted agents. They discuss how these findings may refine treatment selection, deepen understanding of MRD-guided care, and influence long-term management strategies. They also identify emerging areas of scientific interest that may define the next wave of innovation in ALL research.

Videos

Other Possible Research Avenues for Blinatumomab in ALL

Jonathan Webster, MD, and Nikesh Shah, MD, explore future research directions for blinatumomab in ALL, including combination strategies, sequencing questions, and potential synergy with next-generation targeted agents. They also consider how novel immunotherapies and evolving MRD-driven treatment paradigms may shape upcoming clinical investigations.

Ongoing research explores the logistics and efficacy of blinatumomab, aiming to enhance patient access and treatment outcomes in leukemia therapy.

Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Jonathan Webster, MD, and Nikesh Shah, MD, review data on the clinical activity of blinatumomab in younger adults with 

–negative B-cell ALL, focusing on remission depth and survival outcomes. They highlight how early integration of blinatumomab can enhance MRD clearance and potentially reduce the need for more intensive therapies. Webster and Shah also discuss emerging evidence suggesting particularly meaningful benefit in this younger patient population.

Jonathan Webster, MD, and Nikesh Shah, MD, discuss data for blinatumomab in younger adult patients with BCR:ABL1–negative B-ALL.

Role of Age and Ph Status in Blinatumomab Selection in ALL

Jonathan Webster, MD, and Nikesh Shah, MD, describe how patient age and Philadelphia chromosome (Ph) status influence the decision to incorporate blinatumomab (Blincyto) into an ALL treatment plan. They discuss how younger adults, older adults, and patients with Ph-positive or Ph-negative disease may derive different levels of benefit based on disease biology and treatment tolerance. They also outline how these factors guide personalized treatment algorithms and optimize therapeutic outcomes.

Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL. 

How Blinatumomab Is Utilized in ALL Management

Jonathan Webster, MD, and Nikesh Shah, MD, examine the expanding role of blinatumomab (Blincyto) across multiple stages of ALL therapy, including its use in consolidation, minimal residual disease (MRD)–directed treatment, and relapse settings. They discuss the clinical benefits of this bispecific T-cell engager, such as its ability to achieve deep molecular responses and reduce relapse risk. Webster and Shah also address practical considerations, including administration logistics and toxicity monitoring.

Jonathan Webster, MD, and Nikesh Shah, MD, explore the current role of blinatumomab in acute lymphoblastic leukemia management.

Current Frontline Treatment Considerations in Acute Lymphoblastic Leukemia

Jonathan Webster, MD, and Nikesh Shah, MD, outline current frontline treatment strategies in acute lymphoblastic leukemia (ALL), emphasizing how risk stratification, molecular profiling, and patient fitness guide regimen selection. They highlight key distinctions between pediatric-inspired and adult-based approaches, noting how these paradigms continue to evolve with emerging clinical evidence. Webster and Shah also address persistent challenges in early disease management, including toxicity mitigation and optimal integration of immunotherapies.

Jonathan Webster, MD, and Nikesh Shah, MD, detail current treatment approaches in frontline acute lymphoblastic leukemia.